

# Isabell Witzel

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6575166/isabell-witzel-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

59  
papers

978  
citations

19  
h-index

29  
g-index

64  
ext. papers

1,286  
ext. citations

4.1  
avg, IF

3.95  
L-index

#	Paper	IF	Citations
59	54/w mit einem Tastbefund in der rechten Brust. <i>Onkologe</i> , <b>2022</b> , 28, 159	0.1	
58	Update Breast Cancer 2022 Part 1 [Early Stage Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , <b>2022</b> , 82, 580-589	2	
57	Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design. <i>Scientific Reports</i> , <b>2021</b> , 11, 20178	4.9	
56	6q deletion is frequent but unrelated to patient prognosis in breast cancer. <i>Breast Cancer</i> , <b>2021</b> , 1	3.4	
55	Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 515-515	2.2	0
54	The effect of family history on screening procedures and prognosis in breast cancer patients - Results of a large population-based case-control study. <i>Breast</i> , <b>2021</b> , 55, 98-104	3.6	2
53	MUC5AC expression is linked to mucinous/endometrioid subtype, absence of nodal metastasis and mismatch repair deficiency in ovarian cancer. <i>Pathology Research and Practice</i> , <b>2021</b> , 224, 153533	3.4	1
52	High mitochondrial content is associated with breast cancer aggressiveness. <i>Molecular and Clinical Oncology</i> , <b>2021</b> , 15, 203	1.6	1
51	Molecular Mechanisms Associated with Brain Metastases in HER2-Positive and Triple Negative Breast Cancers. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
50	Evaluation of a program for routine implementation of shared decision-making in cancer care: results of a stepped wedge cluster randomized trial.. <i>Implementation Science</i> , <b>2021</b> , 16, 106	8.4	2
49	Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	6
48	High homogeneity of MMR deficiency in ovarian cancer. <i>Gynecologic Oncology</i> , <b>2020</b> , 156, 669-675	4.9	13
47	Targeting the Human Epidermal Growth Factor Receptor Family in Breast Cancer beyond HER2. <i>Breast Care</i> , <b>2020</b> , 15, 579-585	2.4	2
46	Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1013-1013	2.2	18
45	Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases. <i>Cancers</i> , <b>2020</b> , 12,	6.6	4
44	Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer. <i>Breast Care</i> , <b>2020</b> , 15, 608-618	2.4	3
43	Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2020</b> , 179, 403-414	4.4	9

42	Highlights from the San Antonio Breast Cancer Symposium (SABCS) 2019. <i>Breast Care</i> , <b>2020</b> , 15, 192-196.	2.4	4
41	Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial. <i>Cancers</i> , <b>2019</b> , 11,	6.6	5
40	Clonality of circulating tumor cells in breast cancer brain metastasis patients. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 101	8.3	31
39	AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. <i>Breast Care</i> , <b>2019</b> , 14, 247-255	2.4	23
38	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. <i>Breast Care</i> , <b>2019</b> , 14, 224-245	2.4	53
37	Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto. <i>Breast Cancer Research</i> , <b>2019</b> , 21, 60	8.3	11
36	A shift from membranous and stromal syndecan-1 (CD138) expression to cytoplasmic CD138 expression is associated with poor prognosis in breast cancer. <i>Molecular Carcinogenesis</i> , <b>2019</b> , 58, 2306-2315	5.15	8
35	Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. <i>Aging</i> , <b>2019</b> , 11, 7796-7804	5.6	20
34	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. <i>Scientific Reports</i> , <b>2019</b> , 9, 2318	4.9	19
33	Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 1009-1015	8.7	6
32	Adaptation and qualitative evaluation of encounter decision aids in breast cancer care. <i>Archives of Gynecology and Obstetrics</i> , <b>2019</b> , 299, 1141-1149	2.5	7
31	Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer. <i>British Journal of Cancer</i> , <b>2018</b> , 118, 847-856	8.7	30
30	The clinical relevance of serum vascular endothelial growth factor (VEGF) in correlation to circulating tumor cells and other serum biomarkers in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 172, 93-104	4.4	14
29	Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer. <i>BMC Cancer</i> , <b>2018</b> , 18, 541	4.8	6
28	Evaluation of a program for routine implementation of shared decision-making in cancer care: study protocol of a stepped wedge cluster randomized trial. <i>Implementation Science</i> , <b>2018</b> , 13, 51	8.4	15
27	Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. <i>European Journal of Cancer</i> , <b>2018</b> , 102, 1-9	7.5	41
26	Role of HYAL1 expression in primary breast cancer in the formation of brain metastases. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 162, 427-438	4.4	5
25	Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience. <i>Breast Cancer Research and Treatment</i> , <b>2017</b> , 163, 517-526	4.4	15

24	Efficacy of Liposomal Cytarabine in the Treatment of Leptomeningeal Metastasis of Breast Cancer. <i>Breast Care</i> , <b>2017</b> , 12, 165-167	2.4	8
23	Ber 5 Jahre hinaus verlängerte endokrine Therapie. <i>Onkologe</i> , <b>2017</b> , 23, 573-574	0.1	
22	Systemic Treatment Options for HER2-Positive Breast Cancer Patients with Brain Metastases beyond Trastuzumab: A Literature Review. <i>Breast Care</i> , <b>2017</b> , 12, 168-171	2.4	16
21	Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. <i>Scientific Reports</i> , <b>2017</b> , 7, 17307	4.9	9
20	PTEN mediates the cross talk between breast and glial cells in brain metastases leading to rapid disease progression. <i>Oncotarget</i> , <b>2017</b> , 8, 6155-6168	3.3	23
19	Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients. <i>Anticancer Research</i> , <b>2017</b> , 37, 3117-3128	2.3	12
18	Comparison of nine prognostic scores in patients with brain metastases of breast cancer receiving radiotherapy of the brain. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2016</b> , 142, 325-32	4.9	4
17	What do women with breast cancer expect from their treatment? Correlates of negative treatment expectations about endocrine therapy. <i>Psycho-Oncology</i> , <b>2016</b> , 25, 1485-1492	3.9	22
16	Breast cancer brain metastases: biology and new clinical perspectives. <i>Breast Cancer Research</i> , <b>2016</b> , 18, 8	8.3	152
15	Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): Treatment patterns and clinical outcome of more than 1000 patients with brain metastases from breast cancer.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2070-2070	2.2	1
14	p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 81322-81331	3.3	24
13	Radiological Patterns of Brain Metastases in Breast Cancer Patients: A Subproject of the German Brain Metastases in Breast Cancer (BMBC) Registry. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	14
12	Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer. <i>Frontiers in Oncology</i> , <b>2015</b> , 5, 211	5.3	15
11	Relevance of Gal-GalNAc-containing glycans and the enzymes involved in their synthesis for invasion and survival in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , <b>2015</b> , 151, 515-284	4.4	23
10	Prognostic relevance of glycosylation-associated genes in breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2014</b> , 145, 295-305	4.4	64
9	Long-term tumor remission under trastuzumab treatment for HER2 positive metastatic breast cancer - results from the HER-OS patient registry. <i>BMC Cancer</i> , <b>2014</b> , 14, 806	4.8	20
8	Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. <i>Oncotarget</i> , <b>2014</b> , 5, 3076-87	3.3	29
7	Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2013</b> , 139, 809-16	4.9	24

6	Frequent genetic alterations in EGFR- and HER2-driven pathways in breast cancer brain metastases. <i>American Journal of Pathology</i> , <b>2013</b> , 183, 83-95	5.8	50
5	Detection of activated leukocyte cell adhesion molecule in the serum of breast cancer patients and implications for prognosis. <i>Oncology</i> , <b>2012</b> , 82, 305-12	3.6	23
4	Clinical relevance of loss of 11p15 in primary and metastatic breast cancer: association with loss of PRKCDBP expression in brain metastases. <i>PLoS ONE</i> , <b>2012</b> , 7, e47537	3.7	15
3	Management of patients with brain metastases receiving trastuzumab treatment for metastatic breast cancer. <i>Onkologie</i> , <b>2011</b> , 34, 304-8		13
2	Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. <i>Breast Cancer Research and Treatment</i> , <b>2010</b> , 123, 437-45	4.4	38
1	Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer. <i>Breast Care</i> , 1-9	2.4	1